Optimized Purification Platform Speeds mAbs Production
WEBINAR
Getting your antibody to clinical trials faster while being able to build a robust, scalable, and high-yielding process is a challenge many biotech companies face. By outsourcing to a CTDMO, you can benefit from an optimized platform process. In this webinar, we will showcase our purification development platform, including an MMC (mixed-mode chromatography) step and how it allowed our client Igyxos Biotherapeutics to simplify and accelerate their clinical trial supply while achieving high-quality material.
In this webinar, you will learn how a process platform can help:
- Accelerate your development journey
- Facilitate transfer and scale-up to production
- Gain knowledge on the molecule
Speakers
Marie Cecille
Merck
Head of CMC Leaders
Marie Cecille has a master’s degree in biotechnology and bioengineering. After spending a few years as a consultant on the management of products and processes within the pharmaceutical industry, she joined Merck in 2021 and became the head of CMC leaders in 2023. Since then, she has actively helped CDMO customers to succeed in the technical and CMC strategy of their clinical and commercial projects.
Thierry Ziegler
Igyxos
Chief Operation Officer
Thierry Ziegler joined Igyxos in February 2021 as Chief Operating Officer. He is in charge of the coordination of the company’s IGX12 mAb CMC development from cell line generation to IMP manufacturing.
During his career at Serono Healthcare, Sanofi, and Cellectis, Thierry was responsible for managing the development and production of multiple monoclonal antibodies as well as many other types of biologics modalities ranging from recombinant proteins to CAR-T cells. He is familiar with the CMC and regulatory aspects of Biologics from clinical development to life cycle management.
Thierry is a bioprocess engineer and obtained his Ph.D. at the Georgia Institute of Technology.
Pharma and biopharma manufacturing
- Pharma and biopharma manufacturing
Duration:1h
Language:English
Session 1:presented March 23, 2023